Company Overview of Bayer HealthCare AG
Bayer HealthCare AG discovers, develops, manufactures, and markets products that help to prevent, diagnose, and treat diseases for humans and animals worldwide. The company operates through four divisions: Animal Health, Consumer Care, Medical Care, and Pharmaceuticals. The Animal Health division produces and distributes various animal health and care products, which include flea and tick-control solutions, anti-infective products, and endoparasitics for farm and companion animals. The Consumer Care division offers over-the-counter products, such as analgesics, gastrointestinal products, dermatological/topical products, cough and cold remedies, and multivitamins and dietary supplements. It s...
Building Q 30
Founded in 1863
49 214 301
49 214 30 50731
Key Executives for Bayer HealthCare AG
Chairman of Management Board
Chief Financial Officer and Head of Central Administration & Organization
Chief Operating Officer of Bayer CropScience and Member of Executive Committee
Head of Global Drug Discovery
Senior Vice President and Region Head of Consumer Care Division - North America
Compensation as of Fiscal Year 2016.
Bayer HealthCare AG Key Developments
Bayer Healthcare Receives Approval for EYLEA Injection
Nov 8 15
Regeneron Pharmaceuticals announced that Bayer HealthCare has received European approval for EYLEA (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization. Myopic CNV is an eye disease associated with high degrees of myopia (near-sightedness) and frequently affects people of working age. In a release, the company noted that in the EU, EYLEA is already approved for the treatment of patients with neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, and visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO). In Japan, EYLEA is approved for the treatment of visual impairment due to myopic choroidal neovascularization, age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) and diabetic macular edema.
Regeneron Pharmaceuticals, Inc. and Bayer Healthcare Receive European Approval for EYLEA
Oct 30 15
Regeneron Pharmaceuticals, Inc. announced that Bayer HealthCare has received European approval for EYLEA (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization. Myopic CNV is an eye disease associated with high degrees of myopi. Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies share equally the profits from sales of EYLEA, except for Japan.
Bayer HealthCare Announces Earnings Results for the Third Quarter and Nine Months of 2015
Oct 29 15
Bayer HealthCare announced earnings results for the third quarter and nine months of 2015. For the quarter, the company reported sales of EUR 5,651 million compared to EUR 4,740 million a year ago. EBIT was EUR 1,219 million compared to EUR 1,062 million a year ago. EBIT before special items was EUR 1,265 million compared to EUR 1,008 million a year ago. EBITDA was EUR 1,633 million compared to EUR 1,422 million a year ago. EBITDA before special items was EUR 1,677 million compared to EUR 1,368 million a year ago.
For the nine months, the company reported sales of EUR 17,063 million compared to EUR 13,724 million a year ago. EBIT was EUR 3,273 million compared to EUR 2,920 million a year ago. EBIT before special items was EUR 3,609 million compared to EUR 2,875 million a year ago. EBITDA was EUR 4,599 million compared to EUR 3,997 million a year ago. EBITDA before special items was EUR 4,908 million compared to EUR 3,948 million a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|